Factors Associated With Improved A1C Values Among People Using High-Dose Insulin With Uncontrolled Type 2 Diabetes

Overview

Journal Clin Diabetes

Specialty Endocrinology

Date 2024 Jan 17

PMID 38230337

Authors

Wuenseslao Hernandez

Shannon R Walter

Ryan A Popp

Affiliations

Soon will be listed here.

Abstract

Uncontrolled diabetes negatively affects millions of people in the United States and contributes to significant health burden. Many people with diabetes require high insulin doses to achieve glycemic control, but glycemia in this group has historically been difficult to manage. This retrospective, case-control study evaluated which therapeutic interventions and patient factors were associated with an improvement in A1C in people with type 2 diabetes using high-dose insulin at a county health system serving primarily low-income patients. Medication nonadherence was found to be the most influential factor affecting glycemic control in these individuals.

References

Lane W, Weinrib S, Rappaport J . The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements. Diabetes Technol Ther. 2011; 13(5):592-5. DOI: 10.1089/dia.2010.0221. View

Krass I, Schieback P, Dhippayom T . Adherence to diabetes medication: a systematic review. Diabet Med. 2014; 32(6):725-37. DOI: 10.1111/dme.12651. View

Fang M, Wang D, Coresh J, Selvin E . Trends in Diabetes Treatment and Control in U.S. Adults, 1999-2018. N Engl J Med. 2021; 384(23):2219-2228. PMC: 8385648. DOI: 10.1056/NEJMsa2032271. View

Church T, Haines S . Treatment Approach to Patients With Severe Insulin Resistance. Clin Diabetes. 2016; 34(2):97-104. PMC: 4833480. DOI: 10.2337/diaclin.34.2.97. View

Walter S, Popp R . Factors Associated With Improved A1C Values Among People With Uncontrolled Type 2 Diabetes. Clin Diabetes. 2022; 40(4):458-466. PMC: 9606554. DOI: 10.2337/cd21-0120. View

OValle F . Clinical approach to the patient with diabetes mellitus and very high insulin requirements. Diabetes Res Clin Pract. 2010; 90(3):231-42. DOI: 10.1016/j.diabres.2010.06.025. View

. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2021; 45(Suppl 1):S17-S38. DOI: 10.2337/dc22-S002. View

Patel S, Abreu M, Tumyan A, Adams-Huet B, Li X, Lingvay I . Effect of medication adherence on clinical outcomes in type 2 diabetes: analysis of the SIMPLE study. BMJ Open Diabetes Res Care. 2019; 7(1):e000761. PMC: 6887507. DOI: 10.1136/bmjdrc-2019-000761. View

Curtis S, Boye K, Lage M, Garcia-Perez L . Medication adherence and improved outcomes among patients with type 2 diabetes. Am J Manag Care. 2017; 23(7):e208-e214. View

10.

Castellana M, Cignarelli A, Brescia F, Laviola L, Giorgino F . GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis. Diabetes Metab Res Rev. 2018; 35(1):e3082. DOI: 10.1002/dmrr.3082. View

11.

Stolpe S, Kroes M, Webb N, Wisniewski T . A Systematic Review of Insulin Adherence Measures in Patients with Diabetes. J Manag Care Spec Pharm. 2016; 22(11):1224-1246. PMC: 10398138. DOI: 10.18553/jmcp.2016.22.11.1224. View

12.

Lebovitz H . Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes. 2001; 109 Suppl 2:S135-48. DOI: 10.1055/s-2001-18576. View

13.

Juurinen L, Kotronen A, Graner M, Yki-Jarvinen H . Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses. J Clin Endocrinol Metab. 2007; 93(1):118-24. DOI: 10.1210/jc.2007-1825. View

14.

Lau D, Nau D . Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care. 2004; 27(9):2149-53. DOI: 10.2337/diacare.27.9.2149. View